Precigen is trading 4.24% down at $6.89, with biotech-sector weakness potentially weighing on shares; no verified new company-specific announcement has been identified to explain the move.
- XBI was down 2.06% during the regular session.
- A report published October 16 describes an FDA approval, but FDA and company records date PAPZIMEOS approval to 2025, not a new catalyst today.